High-Performance Liquid Chromatography for Ultra-Simple Determination of Plasma Voriconazole Concentration

Yasu, Takeo; Nomura, Yujiro; Gando, Yoshito; Matsumoto, Yasuhiko; Sugita, Takashi; Kosugi, Nobuharu; Kobayashi, Masayuki

doi:10.3390/jof8101035

Cited by 2 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding TDM, there are several methods that can be used to measure the serum concentrations of antifungal drugs, such as liquid chromatography with ultraviolet detection (HPLC-UV), liquid chromatography-mass spectrometry (LC-MS) and surface-enhanced Raman spectroscopy combining chemometrics [98][99][100]. Each technique has advantages and disadvantages, but the LC-MS is in an expanding mode among analytical quantification methods, due to its high sensitivity and specificity.…”

Section: Pharmacogenomics and Therapeutic Drug Monitoringmentioning

confidence: 99%

Antifungals: From Pharmacokinetics to Clinical Practice

Carmo,

Rocha,

Pereirinha

et al. 2023

Antibiotics

View full text Add to dashboard Cite

The use of antifungal drugs started in the 1950s with polyenes nystatin, natamycin and amphotericin B-deoxycholate (AmB). Until the present day, AmB has been considered to be a hallmark in the treatment of invasive systemic fungal infections. Nevertheless, the success and the use of AmB were associated with severe adverse effects which stimulated the development of new antifungal drugs such as azoles, pyrimidine antimetabolite, mitotic inhibitors, allylamines and echinochandins. However, all of these drugs presented one or more limitations associated with adverse reactions, administration route and more recently the development of resistance. To worsen this scenario, there has been an increase in fungal infections, especially in invasive systemic fungal infections that are particularly difficult to diagnose and treat. In 2022, the World Health Organization (WHO) published the first fungal priority pathogens list, alerting people to the increased incidence of invasive systemic fungal infections and to the associated risk of mortality/morbidity. The report also emphasized the need to rationally use existing drugs and develop new drugs. In this review, we performed an overview of the history of antifungals and their classification, mechanism of action, pharmacokinetic/pharmacodynamic (PK/PD) characteristics and clinical applications. In parallel, we also addressed the contribution of fungi biology and genetics to the development of resistance to antifungal drugs. Considering that drug effectiveness also depends on the mammalian host, we provide an overview on the roles of therapeutic drug monitoring and pharmacogenomics as means to improve the outcome, prevent/reduce antifungal toxicity and prevent the emergence of antifungal resistance. Finally, we present the new antifungals and their main characteristics.

show abstract

Section: Pharmacogenomics and Therapeutic Drug Monitoringmentioning

confidence: 99%